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Haloperidol is an antipsychotic drug that inhibits the dopamine D2 receptor among others. Haloperidol
also binds the sigma-1 receptor (s1R) and inhibits it irreversibly. A serious outcome of haloperidol
treatment of schizophrenia patients is death due to sudden cardiac failure. Although the cause remains
unclear, we hypothesized that these effects were mediated by chronic haloperidol inhibition of cardiac
s1R. To test this, we treated neonatal rat cardiomyocytes with haloperidol, exposed them to angiotensin
II and assessed hypertrophy, s1R expression, mitochondrial Ca2þ transport and ATP levels. In this context,
haloperidol treatment altered mitochondrial Ca2þ transport resulting in decreased ATP content by
inactivating cardiac s1R and/or reducing its expression. We also performed transverse aortic constriction
(TAC) and then treated mice with haloperidol. After two weeks, haloperidol-treated mice showed
enhanced heart failure marked by deteriorated cardiac function, reduced ATP production and increasing
mortality relative to TAC only mice. ATP supplementation via sodium pyruvate rescued phenotypes seen
in haloperidol-treated TAC mice. We conclude that s1R inactivation or downregulation in response to
haloperidol treatment impairs mitochondrial Ca2þ mobilization, depleting ATP depletion from car-
diomyocytes. These ﬁndings suggest a novel approach to mitigate haloperidol-related adverse effects in
schizophrenia patients by ATP supplementation.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Haloperidol was introduced as a therapeutic over 40 years ago
and remains widely used clinically to treat acute and chronic psy-
chosis, schizophrenia, and delirium. Antipsychotic activity of
haloperidol is thought to be mediated, at least in part, by its
antagonism (Ki ¼ 2.8 nM) of the dopamine D2 receptor
(8,30,52,56). In addition, haloperidol has comparable afﬁnity for
the sigma-1 receptor (s1R) and is known to act as a s1R inhibitor
(Ki ¼ 3.0 nM) (8,32); however, the consequences of haloperidola, Sendai 980-8578, Japan.
unaga).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).binding to s1Rs are less well known. Studies show that haloperidol
administered at therapeutic doses (0.003 mg/kg), as is used in
humans, can inhibit s1 receptors in vivo (38) and that treatment
reportedly decreases the density of brain s1R in patients (38).
Moreover, several studies show that haloperidol is metabolized
in vivo to a reduced form with higher afﬁnity (in the nanomolar
range) for s1Rs (17,32,52); conversely, reduced haloperidol binds
dopamine receptors with 85-fold lower afﬁnity than haloperidol
(Ki ¼ 239 nM) (8). Acting as an antagonist, the reduced form can
irreversibly inactivate s1Rs in guinea pig brain homogenates and in
SH-SY5Y human neuroblastoma cells (10).
Although haloperidol is generally considered safe, a serious
adverse effect of its use in schizophrenia patients is an abnormal
heart rhythm called torsades de pointes (TdP) and QT prolongation
(QTP), which can lead to sudden death fromheart failure (14,24,42).
These outcomes have been reported following either oral (18,29) ornese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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result of overdose (23). The Food and Drug Administration (FDA)
reported a total of 70 cases of intravenous haloperidol
administration-associated fatal events (like QTP and/or TdP) and
has warned patients about these potential outcomes (34). Molec-
ular mechanisms underlying cardiotoxic effects remain unclear. We
proposed that adverse cardiac effects of haloperidol are mediated
by inhibition of cardiac s1Rs, which we conﬁrmed to be abundantly
expressed in mouse heart (7,16). We also reported that s1R activity
is potentially cardioprotective and have shown a direct relationship
between reduced s1R expression and impaired heart function in a
transverse aortic constriction (TAC) mouse model of left ventricular
hypertrophy (47). Our work has conﬁrmed that s1R stimulation
with selective agonists like ﬂuvoxamine or SA4503 in TAC mice
improved cardiac function and reduced cardiac hypertrophy (50).
We also showed that in rat heart, targeting s1R with neurosteroid
dehydroepiandrosterone (DHEA) or pentazocine can promote car-
dioprotection in the context of pressure overload (PO)-induced
cardiac dysfunction (44,46).
s1R is localized in the mitochondria-associated endoplasmic
reticulum (ER) membrane (MAM) where it interacts with the
inositol 1,4,5-trisphosphate receptor (IP3R) to regulate Ca2þ
transport from the ER lumen into mitochondria (22). Car-
diomyocytes express all the three types of IP3Rs (approximate
relative abundance: IP3R1, 25%; IP3R2, 48%; and IP3R3, 27%), and
the three subtypes differ in function, expression pattern and
subcellular localization in different cell types (1,53,55). We pre-
viously reported that perturbation of IP3R-mediated Ca2þ release
plays an important role in development of cardiac hypertrophy,
and that s1R agonists modulate IP3R-mediated Ca2þ release in
cardiomyocytes (44,45). However, it is not known whether
haloperidol-induced inactivation and/or reduction in expression
of cardiac s1R would alter mitochondrial Ca2þ mobilization
through IP3R expressed in cardiomyocytes and thereby promote
adverse cardiac effects.
In this study, we asked whether haloperidol treatment induced
cardiotoxicity mediated by s1R inactivation. We discovered that
haloperidol-induced s1R inactivation exacerbates Ang II-induced
impairment of sarcoplasmic reticulum (SR)-mitochondrial Ca2þ
transport, leading to decreases in mitochondrial ATP production,
which in turn aggravated cardiac contractile dysfunction in TAC
mice. Interestingly, co-administration of an ATP supplement such
as sodium pyruvate restored cardiac ATP levels and ameliorated
haloperidol-induced cardiac contractile dysfunction in TAC mice.
This study suggests that co-administration of an ATP supplement
with therapeutic doses of haloperidol could be beneﬁcial in pre-
venting adverse effects of haloperidol in schizophrenic patients.2. Materials and methods
2.1. Materials
Reagents and antibodies were obtained from the following
sources: anti-s1R antibody (Abcam, Cambridge, UK); anti-
voltage-dependent anion channel (VDAC) antibody (Cell
Signaling Technology, Beverly, MA); anti-p62 antibody (MBL,
Nagoya, Japan); anti-LC3 antibody (MBL); anti-cytochrome c
antibody (BD Biosciences, San Diego, CA); anti-b-tubulin anti-
body (Sigma, St. Louis, MO). Haloperidol was purchased from
Dainippon Sumitomo Pharma Co. Ltd. (Osaka, Japan). Other re-
agents were of the highest quality available (Wako Pure Chem-
icals, Osaka, Japan). The s1R agonist SA4503 was synthesized in
the Laboratory of Medicinal Chemistry, Zhejiang University
(Hangzhou, China).2.2. Animals and operations
All procedures for handling animals complied with the Guide for
Care and Use of Laboratory Animals and were approved by the An-
imal Experimentation Committee of Tohoku University Graduate
School of Pharmaceutical Sciences. Adult male ICR mice weighing
35e40 g were obtained from Nippon SLC (Hamamatsu, Japan). Ten-
week-old males were acclimated to the local environment for 1
week, which included housing in polypropylene cages at 23 ± 1 C
in a humidity-controlled environment maintained on a 12-h light/
dark schedule (lights on 8:00 AMe8:00 PM). Mice were provided
food and water ad libitum. Transverse aortic constriction (TAC) was
performed as described (44,50) on male ICR mice under anesthesia
using a mixture of ketamine (100 mg/kg, i.p.) (Daiichi Sankyo
Pharmaceutical Co. Ltd, Tokyo, Japan) and xylazine (5 mg/kg, i.p.)
(Sigma). Adequate depth of anesthesia was conﬁrmed by a negative
toe-pinch reﬂex. If anesthesia was not sufﬁcient, then a top-up dose
of 20% of the initial dose was given.2.3. Experimental design
ICR mice were randomly separated into seven experimental
groups: 1) Sham (n ¼ 5), 2) Sham plus sodium pyruvate (Pyr)
treatment (1.0 mg/kg, p.o.) (n ¼ 4), 3) Sham plus haloperidol (Halo)
treatment (0.1 mg/kg, p.o.) (n ¼ 6), 4) TAC plus vehicle treatment
(n ¼ 9), 5) TAC plus sodium pyruvate treatment (n ¼ 5), 6) TAC plus
haloperidol treatment (n ¼ 10), and 7) TAC plus haloperidol plus
sodium pyruvate treatment (n ¼ 11). Vehicle, sodium pyruvate and
haloperidol were administered orally for 2 or 4 weeks (once daily)
using a metal gastric zonde for mice in a volume of 1 ml/100 g of
mouse body weight, starting from the onset of aortic banding.2.4. Echocardiography and measurement of cardiac hypertrophy
Noninvasive echocardiographic measurements were performed
as described (47,50). Brieﬂy, noninvasive echocardiographic mea-
surements were performed in mice anesthetized with a mixture of
ketamine (100 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.) using ul-
trasonic diagnostic equipment (SSD-6500; Hitachi-Aloka, Tokyo,
Japan) equipped with a 10-MHz linear array transducer (UST-5545;
Hitachi-Aloka). The heart was imaged in the two-dimensional
parasternal short-axis view, and an M-mode echocardiogram of
the mid-ventricle was recorded at the level of the papillary mus-
cles. Diastolic and systolic LV wall thickness, LV end-diastolic
diameter (LVEDD), LV end-systolic diameter (LVESD) and ejection
fraction (EF) were measured. All measurements were done from
leading edge to leading edge according to the American Society of
Echocardiography guidelines. The percentage of LV fraction short-
ening (FS) was calculated as ([LVEDD  LVESD]/LVEDD)  100.
Following sacriﬁce by cervical spine fracture dislocation, the
thoracic cavity of mice was opened, and hearts were immediately
harvested and weighed.2.5. Cultured cardiomyocytes
Neonatal rat ventricular cardiomyocytes (NRVMs) were isolated
from hearts of 1 to 3-day-old Wistar rat pups that had been sacri-
ﬁced by decapitation, and cardiomyocytes were cultured as
described (47,50). In the experiments that followed, cells were
stimulated with Ang II (100 nM), haloperidol (10 nM) or SA4503
(1 mM) for 1 or 48 h.
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cardiomyocytes and histological analysis of cardiac tissues
Morphological analysis was performed as described (44). The
surface area of control cells was deﬁned as 100% and then
compared with that of treated cells. For mitochondrial staining,
cells were stained for 20 min with 0.02 mM Mito Tracker Red
CMXRos (Molecular Probes, Eugene, OR) before ﬁxation (12). After
permeabilization with 0.1% Triton X-100 in PBS, ﬁxed cells were
incubated with 1% bovine serum albumin (BSA) (Sigma) in PBS for
30 min. For immunocytochemistry, cells were incubated 24 h at
4 C with anti-LC3 antibody (1:500), anti-p62 antibody (1:500) or
anti-cytochrome c antibody (1:500) in PBS containing 1% BSA. After
washing, cells were incubated 24 h with Alexa 488-conjugated
anti-rabbit IgG and Alexa 488-conjugated phalloidin and/or Alexa
594-conjugated anti-mouse IgG (Invitrogen, Carlsbad, CA) in PBS
containing 1% BSA. For nuclear staining, sections were incubated
with 40,6-diamidino-2-phenylindole dihydrochloride (DAPI)
(Sigma; 1 mg/mL PBS). Immunoﬂuorescent images were analyzed
using a confocal laser scanning microscope (LSM700; Zeiss,
Thornwood, NY). Quantitative analyses of cell size, ﬂuorescence
intensity of Mito Tracker and LC3 granules were undertaken using
ImageJ software. Speciﬁcally, after image capture, lines surrounding
each cell were drawn and signal intensity inside those lines was
determined using ImageJ software.
Histological analysis was performed as described (44). Brieﬂy,
ﬁxed and dehydrated murine heart was embedded in O.C.T. com-
pound (Sakura Finetek, Torrance, CA) and sliced. For Masson's tri-
chrome staining, 20-mm slice tissues were stained using a Trichrome
Stain (Masson) Kit (Sigma) according to manufacturer's protocol.
2.7. Western blot analysis and measurement of ATP content
Dissected LV tissue samples were rapidly frozen in liquid ni-
trogen and stored at 80 C before analysis (47). In the case of
cardiomyocytes, cells were washed with PBS at 4 C and stored
at 80 C until immunoblotting was performed as described
(46,50). For assays, each frozen sample was homogenized as
described (44,49). ATP measurement was performed using an ATP
assay kit (Toyo Ink, Tokyo, Japan), according to the manufacturer's
protocol (50). Brieﬂy, frozen samples were homogenized in ho-
mogenate buffer (0.25M sucrose, 10 mMHEPES-NaOH: pH 7.4), and
lysates were cleared by centrifugation at 1000 g for 10 min at 4 C.
The supernatant was collected, and supernatant proteins were
solubilized in extraction buffer. After 30 min, luciferin buffer was
added to each sample and oxyluciferin was detected using a
luminometer (Gene Light 55, Microtec, Funabashi, Japan).
2.8. Real-time PCR
Total RNA from LV tissues was isolated using TRI Reagent
(Sigma). Brieﬂy, LV tissues were homogenized in TRI Reagent and
passed through 23-gauge needle ten times on ice. Chloroform was
added to homogenates, and the mixture was kept on ice for 15 min
and then centrifuged at 15,000 rpm for 5 min at 4 C. The top layer
of supernatant was collected and combined with one volume of
isopropanol and then centrifuged at 15,000 rpm for 20 min at 4 C.
Resulting RNA pellets were washed with 75% ethanol and sus-
pended in sterile water containing 0.1% diethyl pyrocarbonate
(Sigma) to block RNA degradation. cDNAs were synthesized by
reverse transcription as described (40). Real-time PCR was per-
formed with iQ CYBR Green Supermix (Bio-Rad Laboratories, Red-
mond, WA) following the manufacturer's protocol. The primers
were: mouse forward Anp, 50- GTCCAACACAGATCTGATGG -30;
reverse Anp, 50- GATTTGGCTGTTATCTTCGG -30; mouse Gapdhforward, 50- TGTGTCCGTCGTGGATCTGA -30; and reverse Gapdh, 50-
CACCACCTTCTTGATGTCATCATAC -30.
2.9. Measurement of intracellular Ca2þ levels
NRVMs were cultured on 0.01% poly-L-lysine (Sigma)-coated
glass-bottom dishes and maintained in growth medium. After
stimulation with 100 nM Ang II for either 48 or 72 h, myocytes
were loaded with the Ca2þ-sensitive dye Fura-2 acetoxymethyl
ester (2.5 mM; Sigma) for 30 min before measuring Ca2þ levels in a
chamber on an inverted microscope stage. Cells were perfused with
normal Tyrode solution containing 150 mM NaCl, 4 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 5.6 mM glucose, and 5 mM HEPES at 37 C.
When Ca2þ ﬂuorescence levels reached a steady state, 10 mM
phenylephrine (PE) or 10 mM ATP was applied for 10 s through a
small perfusion pipe. The amplitude of the PE- or ATP-induced Ca2þ
transient was used as an index of IP3R-mediated Ca2þ release.
Changes in PE- or ATP-induced Ca2þ release from the SR were
determined using the ratio of ﬂuorescence emission at 530 nm in
response to excitation at 340 nm and to that at 380 nm.
2.10. Measurement of mitochondrial Ca2þ levels
NRVMs were cultured on 0.01% poly-L-lysine (Sigma)-coated
glass-bottom dishes and maintained in growth medium. Trans-
fections were performed with ratiometric-pericam targeted to the
mitochondrial matrix (ratiometric-pericam-mt/pcDNA3), which
was a kind gift of Dr. Atsushi Miyawaki of the RIKEN Brain Science
Institute (Wako, Japan) (35,40,50). Brieﬂy, 1 mg/mL ratiometric-
pericam-mt/pcDNA3 in 1 mL was added to 199 mL opti-MEM (Invi-
trogen), and 1 ml Lipofectamine 2000 (Invitrogen) was added to 9 mL
opti-MEM. Both solutions were incubated separately at room tem-
perature for 5 min and then mixed and incubated at room tem-
perature for 15e20 min. Cells were incubated with 800 mL of opti-
MEM to which 200 mL of the ratiometric-pericam-mt/pcDNA3 so-
lution had been added. Cells were then incubated at 37 C in a 5%
CO2 atmosphere for 4 h to initiate transfection. Then, 500 ml DMEM
supplemented with 5% FBS was added to each well to maintain cell
viability. After 24 h, 100 nM Ang II was added. After stimulation for
48 h, cells were perfused with normal Tyrode solution at 37 C.
When Ca2þ ﬂuorescence levels reached a steady state, 10 mM PE or
10 mMATPwas applied for 10 s through a small perfusion pipe. Dual-
excitation imagingwith ratiometric-pericam-mt required two ﬁlters
(EX:482/35, DM:506, EM:536/40 and EX:414/46, DM:510, EM:527/
20). Changes in PE- or ATP-induced Ca2þ transport from the SR to
mitochondria were determined using the Metaﬂuor Imaging system
(Molecular Devices, Sunnyvale, CA).
2.11. TUNEL staining
Double-staining for TUNEL to detect apoptotic cell nuclei and
propidium iodide to detect myocardial cell nuclei was described
previously (40). TUNEL staining was performed using an in situ
apoptosis detection kit (Takara Bio Inc., Shiga, Japan), according to
the manufacturer's protocol. Cardiomyocytes from at least four
randomly selected slides per block were evaluated immunohis-
tochemically to determine the number and percentage of cells
exhibiting staining indicative of apoptosis. The index of apoptosis
(number of apoptotic myocytes/the total number of myocytes
counted  100%) was determined.
2.12. Statistical analysis
Values are represented as means ± standard error of the mean
(S.E.M.). Comparison between two experimental groups was made
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cardiomyocyte size. In other experiments, differences were evalu-
ated using analysis of variance (ANOVA) followed by multiple
comparisons using Dunnett's test, except for NRVM morphological
measurement. Results related to NRVM area were evaluated by
Scheffe's test to test the effect of SA4503. Survival probability was
calculated by KaplaneMeier analysis, and statistical signiﬁcance
was analyzed by Log-rank test. P < 0.05 was considered statistically
signiﬁcant. F and P values are reported in corresponding ﬁgure
legends.
3. Results
3.1. Haloperidol treatment of cultured cardiomyocytes enhances
Ang II-induced hypertrophy and mitochondrial dysfunction
We previously reported that s1R is abundantly expressed in
rodent cardiomyocytes and showed that s1R activation with a va-
riety of agonists was cardioprotective in vitro and in vivoFig. 1. Effects of haloperidol treatment on Ang II-induced hypertrophy and mitochondr
phalloidin (green), Mito Tracker Red CMXRos (red) and DAPI (blue) and assessed by ﬂuore
untreated control cells. Fifty cells were counted in each experiment. F(7, 408) ¼ 18.680, P <
relative to untreated control cells. Six to nine randomly selected ﬁelds were counted in each
treated 48 h with or without Ang II or haloperidol (Halo). b-tubulin staining serves as a loadi
of 4 samples. E: TUNEL-positive cells were counted in cultures treated 48 h with or witho
experiment. F(3, 19) ¼ 3.086, P < 0.05. Data are expressed as percentages of control values (m
Halo-treated cells; y, P < 0.05 and yy, P < 0.01 vs. Ang II-treated cells; ‡, P < 0.05 and ‡‡, P(2e4,44e47,50). Thus, we reasoned that haloperidol, acting as an
irreversible s1R antagonist, could aggravate Ang II-induced hy-
pertrophy via s1R inactivation (10) and/or by reducing s1R
expression in cardiomyocytes (38). To assess this possibility, we
ﬁrst observed the size of NRVMs exposed to Ang II (100 nM) for 48 h
with or without haloperidol treatment. Treatment with Ang II only
signiﬁcantly increased cell size relative to that of untreated controls
(P < 0.05 vs. control) (Fig. 1A and B). Haloperidol treatment (10 nM)
signiﬁcantly enhanced Ang II-induced cell enlargement (P < 0.01 vs.
control; P < 0.05 vs. Ang II) (Fig. 1A and B). Haloperidol treatment
alone also induced cardiomyocyte hypertrophy in mock-treated
controls (P < 0.05 vs. control) (Fig. 1A and B). Interestingly, halo-
peridol treatment of Ang II-exposed cells for 48 h signiﬁcantly
reduced expression of s1R protein (P < 0.05 vs. control) (Fig. 1D),
but treatment with either haloperidol or Ang II did not (Fig. 1D). To
conﬁrm that s1R activity was relevant to these effects, we
employed the selective s1R agonist (SA4503) (33). SA4503 co-
administration (1 mM) with haloperidol rescued haloperidol-
induced cardiomyocyte hypertrophy (P < 0.01 vs. haloperidolial structure in cultured cardiomyocytes. A: Cells were stained with Alexa Fluor 488-
scence microscopy. B: Cell size is expressed as a percentage of surface area relative to
0.01. C: Mito Tracker Red CMXRos intensity is expressed as a percentage of surface area
experiment. F(3, 26) ¼ 10.430, P < 0.01. D: Upper, Immunoblot of s1R protein in NRVMs
ng control. Lower, Densitometry analysis of s1R immunoreactive bands. Groups consist
ut Ang II or Halo. Eighty cells from 10 randomly selected ﬁelds were counted in each
ean ± S.E.M.).*, P < 0.05 and **, P < 0.01 vs. control cells; #, P < 0.05 and ##, P < 0.01 vs.
< 0.01 vs. SA4503 () control.
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pentazocine binding to s1R (32,33), suggesting they occupy the
same binding site. Therefore, SA4503 treatment at a relatively high
concentration (1 mM) was sufﬁcient to inhibit haloperidol (10 nM)
binding in s1R-induced function. These ﬁndings suggest that
haloperidol directly acts on the cardiac s1R to enhance Ang II-
induced cardiomyocyte enlargement.
We have also reported that treatment of cardiomyocytes with
s1R agonists has antihypertrophic effects in part by preventing
mitochondrial dysfunction (45,50). We extended that analysis toFig. 2. Effects of haloperidol treatment on phenylephrine (PE) and ATP-induced Ca2þ i
induced Ca2þ inﬂux into mitochondria treated 48 h with or without Ang II or Halo. B: Peak in
PE-induced Ca2þ release into the cytosol in cells treated 48 h with or without Ang II or Halo.
course of ATP-induced Ca2þ inﬂux into mitochondria in cells treated 48 h with or without
>10 cells. F(4, 101) ¼ 20.761, P < 0.01. G: Measurement of cellular ATP content with or witho
Data are expressed as percentages of control cell value (mean ± S.E.M.). *, P < 0.05 and **, P <
Ang II-treated cells.deﬁne effect of s1R signaling onmitochondrial membrane potential
under stress conditions, as assessed by Mito Tracker Red CMXRos
staining. Staining intensity of cells treated with Ang II or haloper-
idol signiﬁcantly decreased compared to that of untreated control
cells (44.8% and 51.4% of control, respectively) (P < 0.05 and 0.01 for
haloperidol and Ang II, respectively) (Fig.1A and C). Treatment with
both haloperidol and Ang II signiﬁcantly reduced mitochondrial
membrane potential (P < 0.01 vs. control) (Fig. 1A and C). We also
investigated a potential effect of haloperidol on Ang II-induced
cardiomyocyte apoptosis in cultured cardiomyocytes. Ang II ornﬂux into mitochondria and the cytosol and on ATP content. A: Time course of PE-
creases in [Ca2þ]mito induced by 10 mM PE. F(4, 96) ¼ 14.392, P < 0.01. C: Time courses of
D: Peak increases in [Ca2þ]cyto induced by 10 mM PE. F(4, 89) ¼ 16.579, P < 0.01. E: Time
Ang II. F: Peak increases in [Ca2þ]mito induced by 10 mM ATP. Each group consists of
ut Ang II or Halo treatment. Groups consist of 3e4 samples. F(3, 22) ¼ 9.870, P < 0.01.
0.01 vs. control cells; #, P < 0.05 and ##, P < 0.01 vs. Halo-treated cells; yy, P < 0.01 vs.
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diomyocyte apoptosis, as indicated by a relative increase in the
number of TUNEL-positive cells (P < 0.05 vs. control for both
treatments), while treatment with both signiﬁcantly enhanced
cardiomyocyte apoptosis (P < 0.01 vs. Ang II) (Fig. 1E).
3.2. Effect of haloperidol treatment on phenylephrine (PE)-induced
Ca2þ mobilization and ATP content in NRVMs
Wepreviously reported that s1R activation by agonists regulates
IP3R-mediated Ca2þ release in cardiomyocytes (45,50). Therefore,
we examined the effects of haloperidol treatment on PE-induced
IP3R-mediated Ca2þ mobilization into mitochondria and cytosol
in Ang II-treated cells. Treatment with haloperidol alone for 1 h
slightly suppressed PE-induced mitochondrial Ca2þ transport
relative to controls, an effect that was signiﬁcant after 48 h of
treatment (P < 0.01 for Halo) (Fig. 2A and B). Ang II treatment for
48 h severely impaired PE-induced mitochondrial Ca2þ transport
compared to untreated control cells (P < 0.01 vs. control) (Fig. 2A
and B). Treatment with haloperidol plus Ang II for 48 h signiﬁcantly
enhanced the Ang II response (P < 0.01 vs. Ang II) (Fig. 2A and B).
We also examined the effects of haloperidol on PE-induced IP3R-
mediated Ca2þ release to the cytosol. Neither haloperidol nor Ang II
treatment alone for 1 h or 48 h had a signiﬁcant effect (Fig. 2C and
D); however, combined administration of haloperidol plus Ang II
for 48 h signiﬁcantly increased PE-induced Ca2þ release to the
cytosol (P < 0.01 vs. control and vs. Ang II) (Fig. 2C and D). We also
examined the effects of haloperidol on IP3R-mediated mitochon-
drial Ca2þ mobilization by supplementing Ang II-treated cells with
ATP. Treatment with either haloperidol for 1 or 48 h or Ang II alone
for 48 h had little effect on ATP-induced Ca2þ release to mito-
chondria (Fig. 2E and F). However, combining haloperidol with AngFig. 3. Effects of acute haloperidol or SA4503 treatment on ATP-induced Ca2þmobilizati
mitochondria in cardiomyocytes treated with or without Halo or SA4503 (SA) for 1 h. B: Peak
of ATP-induced Ca2þ release to the cytosol. D: Peak increases in [Ca2þ]cyto induced by 10 m
percentages of control value (mean ± S.E.M.). *, P < 0.05 and **, P < 0.01 vs. control cells; #II treatment for 48 h signiﬁcantly impaired ATP-induced mito-
chondrial Ca2þ transport (P < 0.01 vs. Ang II) (Fig. 2E and F). These
results suggest overall that haloperidol enhances Ang II-induced
impairment of Ca2þmobilization in both mitochondria and cytosol.
We next asked whether s1R inactivation by haloperidol
impaired mitochondrial ATP production in NRVMs. Treatment with
haloperidol alone slightly reduced ATP content relative to un-
treated control cells (Fig. 2G). Consistent with our previous study
(45), Ang II exposure for 48 h increased ATP content (P < 0.01 vs.
control) (Fig. 2G). Interestingly, treatment with haloperidol and
Ang II treatment signiﬁcantly decreased ATP content relative to Ang
II treatment alone (P < 0.01 vs. Ang II) (Fig. 2G). In naive NRVMs,
ATP-induced mitochondrial Ca2þ transport was signiﬁcantly sup-
pressed following acute haloperidol treatment for 1 h (P < 0.05 vs.
control), while co-administration of haloperidol with the s1R
agonist SA4503 eliminated this effect (Fig. 3A and B). By contrast,
ATP-induced Ca2þ release to the cytosol was signiﬁcantly potenti-
ated by haloperidol treatment (P < 0.01 vs. control), which antag-
onized by SA4503 co-administration (P < 0.01 vs. Halo) (Fig. 3C and
D). These observations suggest that s1R inactivation deregulates
mitochondrial Ca2þ mobilization by decreasing ATP content, an
outcome that may underlie haloperidol-induced cardiotoxicity.
3.3. Effects of haloperidol treatment on autophagy and
mitochondrial integrity
Recent reports demonstrate that in cardiomyocytes, multiple
forms of stress, including pressure overload, chronic ischemia, and
ischemia-reperfusion, stimulate increased autophagy, a maladap-
tive response that contributes to heart failure (31,36,57). Given that
Ang II and haloperidol co-administration alters mitochondrial Ca2þ
transport and ATP production, we hypothesized that these effectson into mitochondria and the cytosol. A: Time course of ATP-induced Ca2þ inﬂux into
increases in [Ca2þ]mito induced by 10 mM ATP. F(3, 71) ¼ 4.281, P < 0.01. C: Time courses
M ATP. Groups consist of >10 cells. F(3, 55) ¼ 7.789, P < 0.01. Data are expressed as
, P < 0.05 and ##, P < 0.01 vs. Halo-treated cells.
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possibility by monitoring the autophagic marker LC3 in car-
diomyocytes treatedwith or without Ang II and/or haloperidol. Ang
II treatment alone for 48 h induced a signiﬁcant increase in the
intensity of punctate LC3-positive dots (P < 0.01 vs. control) (Fig. 4A
and B). Moreover, treatment with both haloperidol and Ang II
signiﬁcantly enhanced induction of LC3-positive dots (P < 0.05 vs.
Ang II) (Fig 4A and B), a ﬁnding consistent with earlier studies (57).
Accordingly, we observed induction of expression of p62, a
different marker of autophagy, in cardiomyocytes treated with Ang
II, haloperidol or both (Fig. 4C). Treatment of cardiomyocytes with a
combination of haloperidol and Ang II also elicited a fragmented
staining pattern of the mitochondrial marker, cytochrome c, which
preferentially distributes in tubular and branching pattern in un-
treated control cells (Fig. 4A). Fragmented cytochrome c staining
partially co-localized with LC3 granules, suggesting that mito-
chondria are undergoing mitophagy. We next asked whether
apparent mitochondrial degradation occurred in cardiomyocytes
treated with or without Ang II and/or haloperidol. Combined
treatment with both for 48 h signiﬁcantly decreased expression of
voltage-dependent anion channel (VDAC), a mitochondrial protein
critical for Ca2þ transport with IP3R (P < 0.05 vs. control and
P < 0.01 vs. Ang II) (Fig. 4D and E). Taken together, our ﬁndings
suggest that chronic haloperidol treatment has deleterious effects
on mitochondrial integrity via induction of autophagy in
cardiomyocytes.
3.4. Effects of haloperidol and sodium pyruvate administration on
cardiac hypertrophy and dysfunction in TAC mice
To assess the effect of haloperidol in vivo, we treated both sham-
operated and TAC mice with daily oral administration of haloper-
idol (0.1 mg/kg) beginning two days after surgery. Two weeks later,
treatment groups were analyzed for myocardial hypertrophy based
on assessment of heart weight-to-body weight (HW/BW) ratio,
lung weight-to-body weight (LW/BW) and mRNA levels of atrial
natriuretic peptide (ANP), a hypertrophy marker (Fig. 5AeC). TAC
mice showed signiﬁcantly increased HW/BWand ANPmRNA levels
and moderately increased LW/BW compared to sham mice
(P < 0.01 vs. sham-vehicle in HW/BW and ANP mRNA) (Fig. 5AeC).
Furthermore, haloperidol treatment (0.1 mg/kg) of TAC mice
signiﬁcantly increased the LW/BW ratio (P < 0.01 vs. sham-vehicle
for TAC-haloperidol), an effect not seen in vehicle-treated TAC
controls (Fig. 5B). Given that haloperidol treatment perturbs
mitochondrial ATP production, we supplemented TAC animals with
sodium pyruvate (1.0 mg/kg) to determine whether the haloperidol
effect was due to decreased mitochondrial function. Interestingly,
treatment with both sodium pyruvate (1.0 mg/kg) and haloperidol
prevented TAC and/or haloperidol-induced cardiac hypertrophy
(P < 0.01 vs. TAC-haloperidol) (Fig. 5AeC).
To assess a potential effect of haloperidol treatment on cardiac
remodeling, we measured cardiac ﬁbrosis using Masson's tri-
chrome staining. Interestingly, we observed adverse cardiac
remodeling, as indicated by induction of interstitial ﬁbrosis,
following chronic oral administration of haloperidol toTACmice, an
affect blocked by co-administration of sodium pyruvate (Fig. 5D).
We also assessed cardiac function by echocardiography after
similar treatments (Fig. 5E). Control vehicle-treated TAC mice
showed slightly decreased LC fractional shortening (FS) and ejec-
tion fraction (EF) at 2 weeks after surgery, consistent with our
previous report (47). By contrast, TACmice treated with haloperidol
showed signiﬁcant cardiac dysfunction, as indicated by decreased
FS and EF, compared to vehicle-treated sham mice (P < 0.01 vs.
sham-vehicle) (Fig. 5F and G). All groups showed comparable
LVESD values [F(6, 44) ¼ 1.961, P ¼ 0.0920] (Fig. 5H), haloperidoltreatment on TAC mice elicited only a slight increase in LVESD.
These results suggest that haloperidol induces some indications of
cardiac dysfunction in TAC mice, such as increased LW/BW ratio
(Fig. 5B). Interestingly, co-administration of sodium pyruvate with
haloperidol prevented haloperidol-induced deterioration of cardiac
function and progression of heart failure (P < 0.01 vs. TAC-
haloperidol in FS and EF; P < 0.05 vs. TAC-haloperidol in LVESD)
(Fig. 5EeH). Taken together, we conclude that haloperidol-induced
progression of heart failure is mediated by reduced ATP production
in vivo.
3.5. Effects of haloperidol plus sodium pyruvate treatment on
cardiac s1R expression, ATP content and TAC mouse survival
Earlier studies had reported that haloperidol treatment of hu-
man subjects was accompanied by a decrease in the density of s1R
expression in brain (38). Therefore, we asked whether mice
chronically treated with haloperidol would also exhibit similar
changes in expression pattern in cardiac tissue. Interestingly, after 2
weeks of haloperidol administration, TAC mice showed signiﬁ-
cantly decreased cardiac s1R expression (P < 0.01 vs. sham-vehicle)
(Fig. 6A and B), although untreated and haloperidol-treated sham
mice showed comparable receptor expression (Fig. 6A and B). These
data suggest that cardiac defects seen in TAC mice treated with
haloperidol may be due to decreased s1R expression.
When we examined effects on ATP production we found that
haloperidol treatment of TAC mice signiﬁcantly decreased cardiac
ATP levels relative to sham or TAC mice (P < 0.01 vs. TAC-vehicle)
(Fig. 6C). Interestingly, treatment with sodium pyruvate plus
haloperidol signiﬁcantly and restored ATP content in heart (P< 0.05
vs. TAC-haloperidol) but did not rescue decreased s1R expression
(P < 0.05 vs. sham-vehicle) (Fig. 6AeC). Furthermore,
KaplaneMeier survival analysis showed that chronic haloperidol
treatment increased mortality of TAC mice, with a survival rate of
50% at 14 days and 33% at 28 days (P < 0.05 vs. TAC-vehicle)
compared to 86% survival at 28 days seen in TAC only mice
(Fig. 6D). Sham mice treated with haloperidol showed 100% sur-
vival. Co-administration of sodium pyruvate with haloperidol to
TAC mice prevented haloperidol-induced progression of heart
failure and signiﬁcantly improved mortality (P < 0.05 vs. TAC-
haloperidol). These correlative observations strongly suggest that
deleterious cardiac effects seen following chronic haloperidol
treatment of TAC mice are mediated by decreased s1R expression
and/or inactivation, which in turn promote decreased mitochon-
drial ATP production.
4. Discussion
Recently, we have been exploring the potential beneﬁcial effect
of s1R agonists on the heart, effects which were heretofore un-
derappreciated. Despite the numerous studies analyzing the effects
of s1R ligands in heart tissues, we still do not fully understand how
s1R function is perturbed in pathological states and whether s1R
exists as active state or resting state without stimulation of s1R
ligands. Here, to understand s1R function in heart, we investigated
temporal changes in its expression levels in murine models of
cardiac hypertrophy and heart failure. We have reported that along
with progression of LV hypertrophy, s1R expression was signiﬁ-
cantly reduced in the heart and showed a signiﬁcant positive linear
correlation with heart function (6,47). Our previous studies clearly
demonstrated that s1R activation by selective agonists is car-
dioprotective in rodent models of cardiac hypertrophy and heart
failure (2e7,44e50) Here, we addressed the deleterious effects of
chronic s1R inactivation and decreased expression in heart brought
on by treatment with haloperidol in the progression of heart failure
Fig. 4. Effects of haloperidol treatment on autophagy and mitochondrial structure. A: Cultured cardiomyocytes were assessed using antibodies to LC3 (a marker of autophagy;
green) and Cytochrome c (a mitochondrial marker; Red) and to DAPI (blue) as a nuclear stain. B: Intensity of LC3 staining in granules is expressed as a percentage relative to control
cells. Six to nine randomly selected ﬁelds were counted in each experiment. F(3, 23) ¼ 13.575, P < 0.01. C: Cultured cardiomyocytes were assessed using antibodies to p62 (a marker
of autophagy; green). D: Immunoblot of the mitochondrial protein VDAC in cultured cardiomyocytes treated with or without Ang II or Halo for 48 h. E: Quantiﬁcation by
densitometry of VDAC protein. F(3, 20) ¼ 6.536, P < 0.01. Data are expressed as percentages of control values (mean ± S.E.M.). *, P < 0.05 and **, P < 0.01 vs. control cells; ##, P < 0.01
vs. Halo-treated cells; y, P < 0.05 and yy, P < 0.01 vs. Ang II-treated cells.
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Fig. 5. Effects of haloperidol and sodium pyruvate administration on cardiac hypertrophy and function in TAC mice. A: TAC-induced cardiac hypertrophy, as indicated by the
heart weight/body weight (HW/BW) ratio. F(6, 17) ¼ 14.409, P < 0.01. B: TAC-induced cardiac hypertrophy, as indicated by the lung weight/body weight (LW/BW) ratio. Halo (0.1 mg/
kg) and/or sodium pyruvate (1 mg/kg; Pyr) were administered to sham and TAC mice for 2 weeks after surgery. F(6, 18) ¼ 7.425, P < 0.01. C: Effect of Halo and Pyr treatment on ANP
mRNA levels in TAC and control mice. F(6, 55) ¼ 24.810, P < 0.01. D: Effect of Halo and Pyr on scar formation induced by TAC (Masson's trichrome staining). E: Representative M-
mode echocardiograms of TAC mice treated with and without Halo and Pyr. F: Changes in percentage of LV fractional shortening (FS). F(6, 43) ¼ 3.804, P < 0.01. G: Changes in
percentage of ejection fraction (EF). F(6, 44) ¼ 3.934, P < 0.01. H: Changes in left ventricular end-systolic diameter (LVESD). F(6, 44) ¼ 1.961, P ¼ 0.0920. Groups consist of 5e9 mice.
Each column represents the mean ± S.E.M. **, P < 0.01 vs. sham/vehicle-treated group; #, P < 0.05 and ##, P < 0.01 vs. TAC/vehicle-treated group; yy, P < 0.01 vs. TAC/Halo-treated
group.
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suggest that haloperidol and its more active metabolite irreversibly
inhibit s1R activity and reduce s1R expression levels in vivo
(17,32,52). Although haloperidol treatment was previously re-
ported to have deleterious effects in heart (34), the molecular
mechanisms underlying these effects remained obscure. Here we
report that i) chronic haloperidol treatment decreases s1R
expression, ii) decreases myocardial ATP content, and iii) promotes
adverse myocardial remodeling and deterioration of cardiac func-
tion, which ultimately led to increased mortality of TAC mice.
Combining s1R agonists with ATP supplementation, we conﬁrmed
that the deleterious effects of chronic haloperidol treatment are
mediated by both s1R inactivation and impairedmitochondrial ATP
production.
Here we address mechanisms underlying deleterious effects of
haloperidol on cardiac hypertrophy in vitro and in vivo. We report
that haloperidol treatment impairs ATP production in part byderegulating IP3R-mediated Ca2þ mobilization into mitochondria.
Earlier studies in CHO cells demonstrated that s1R interacts with
IP3R to form a functional complex to regulate Ca2þ entry into
mitochondria, enabling cell survival under stress conditions (22). In
fact, we previously reported that s1R interacts with IP3R in car-
diomyocytes and that s1R activation promotes ATP synthesis by
enhancing Ca2þ entry into mitochondria (44,50). Here, we conﬁrm
that s1R function is cardioprotective in studies showing that s1R
inhibition by haloperidol decreases mitochondrial ATP content:
haloperidol treatment signiﬁcantly suppressed PE- and ATP-
induced mitochondrial Ca2þ transport and potentiated PE- and
ATP-induced Ca2þ release to the cytosol. Treatment with the se-
lective s1R agonist SA4503 completely reversed haloperidol-
induced impairment in Ca2þ mobilization.
We also show that treatment of cardiomyocytes with both
haloperidol and Ang II induces apoptosis, as indicated by the
presence of TUNEL-positive cells, and deregulates autophagy, as
Fig. 6. Effects of combining haloperidol with sodium pyruvate treatment on cardiac s1R expression, ATP content and survival in TAC mice. A: Western blot analysis of s1R
protein in the LV of sham and TAC mice, with or without drug treatment. Anti-b-tubulin staining serves as a loading control. B: Quantiﬁcation by densitometry of s1R immu-
noreactive bands. F(6, 19) ¼ 6.005, P < 0.01. C: ATP content in left ventricles with or without drug treatment. F(6, 34) ¼ 3.436, P < 0.01. *, P < 0.05 and **, P < 0.01 vs. sham/vehicle-
treated group; ##, P < 0.01 vs. TAC/vehicle-treated group; y, P < 0.05 vs. TAC/Halo-treated group. D: KaplaneMeier survival analysis following Halo and Pyr treatment of TAC mice.
Halo and/or Pyr or saline along were administered once daily to sham and TAC mice and survival was monitored over 28 days. In the Log-rank test: P < 0.05 for TAC/Halo vs. TAC/
vehicle-treated group; P < 0.05 for TAC/Halo/Pyr-treated group vs. TAC/Halo-treated group.
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upregulation. Currently it is unclear whether autophagosome
accumulation occurs as a compensatory mechanism to allow
cellular survival under reduced ATP conditions. Interestingly, we
also observed increased mitochondrial fragmentation or degrada-
tion, as indicated by decreased Mito Tracker intensity, increased
LC3/cytochrome c co-localization and decreased VDAC expression,
suggesting that mitochondrial dysfunction occurs as cardiac hy-
pertrophy progresses to heart failure. These observations suggest
that mitochondrial damage triggers apoptosis or autophagy asso-
ciated with mitochondrial energy depletion (21). We also found
that haloperidol treatment remarkably reduced mitochondrial
membrane potential and enhanced similar effects triggered by Ang
II treatment. Ang II exposure generates reactive oxygen species
(ROS) via activation of NADPH oxidase in vascular smooth muscle
and mouse heart (9,37), perturbing mitochondrial function (11,20).
Similarly, haloperidol treatment reportedly increases the presence
of ROS in neurons (39). These reports suggest that Ang II treatment
generates mitochondrial ROS via independent mechanisms.
Further studies are required to deﬁne mechanisms underlying
these outcomes in heart.
We also observed signiﬁcantly increased mortality in
haloperidol-treated TAC mice, with a survival rate of 50% at 14 days
and 33% at 28 days as opposed 86% survival at 28 days seen in TAC
only mice. Mitochondria comprise approximately 30% of the vol-
ume of cardiac muscle. About 70% of ATP generated in heart serves
to fuel contraction, and the remaining 30% provides energy forvarious ion pumps including the Ca2þ-ATPase in SR (SERCA) (19,43).
Cardiac contraction requires ATP production, and impairment in
this process rapidly induces contractile dysfunction (15). Consistent
with these ﬁndings, we found that haloperidol treatment in TAC
mice decreased ATP production and contractile dysfunction.
However, haloperidol treatment of shammice had no adverse effect
on cardiac morphology and function. This result agrees with a
previous report that a total cumulative dose of intravenous halo-
peridol of <2 mg is safe for use for patients who lack cardiovascular
risk factors (34).
Earlier studies of schizophrenia patients combining haloperidol
treatment with supplementation with u-3 polyunsaturated fatty
acid, vitamin E and vitamin C support the idea that potential
deleterious effects of haloperidol could be ameliorated by reducing
oxidative stress (41). Here, we suggest a novel mechanism of ATP
supplementation using sodium pyruvate, the end product of
glycolysis and substrate for acetyl-CoA, combined with haloperidol
treatment. Sodium pyruvate is known to be a safe drug (51) and
exhibits a cardioprotective effect against ischemia-reperfusion
injury in Langendorff-perfused rat hearts (27). Sodium pyruvate
also possesses a therapeutic potential to treat mitochondrial dis-
ease (28). Interestingly, sodium pyruvate combined with haloper-
idol in TACmice blocked adversemyocardial remodeling, perturbed
heart function and progression of heart failure and ultimately
increased animal survival by rescuing mitochondrial ATP levels.
Moreover, administration of intracoronary pyruvate at supra-
physiological concentrations increases cardiac output and
Y. Shinoda et al. / Journal of Pharmacological Sciences 131 (2016) 172e183182decreases pulmonary capillary-wedge pressure and heart rate in
patients with dilated cardiomyopathy and heart failure (25).
Indeed, sodium pyruvate treatment reportedly induces mitochon-
drial biogenesis (54) and can replenish pools of Krebs cycle in-
termediates, enhancing oxidative phosphorylation (13). These
reports support our result that sodium pyruvate prevents
haloperidol-induced progression of heart failure by protecting
mitochondrial function.
5. Conclusions
We have demonstrated that haloperidol treatment in vitro and
in vivo signiﬁcantly decreases expression and activation of cardiac
s1R under stress conditions, which in turn impaired mitochondrial
Ca2þ mobilization and decreased ATP content. These activities
contribute to adverse cardiac remodeling and deterioration of heart
function associated with increasedmortality in haloperidol-treated
TAC mice. We also reported for the ﬁrst time that ATP supple-
mentation via sodium pyruvate rescues ATP levels in haloperidol-
treated TAC mice, enabling proper cardiac contraction and relaxa-
tion. Our study suggests that ATP supplementation could be com-
bined with haloperidol as treatment for serious cases of
schizophrenia, a regime that could mitigate haloperidol's adverse
effects.
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